🌍 Global Spillover Policy Pulse — 24 Jul 2026
1. Strait of Hormuz Crisis Intensifies — Oil Above $100, 13th Night of Strikes
What happened: The US completed its 13th consecutive night of strikes against Iran. Iran rejected a US ceasefire proposal reportedly passed by the Iraqi PM. Houthi allies struck Saudi tankers in the Red Sea. Strait of Hormuz tanker crossings fell to 2-month lows. Oil prices surged above $100/bbl for the first time since May. Indian crude oil futures (MCX) at ₹8,680/bbl (down ₹344 on day but markets still at elevated levels).
Indian angle: IOC and MRPL have already halted Iraq crude loadings due to Hormuz risk. BPCL reported no discounts on Russian crude for September deliveries. India imports ~85% of its crude needs, with ~60% passing through the Strait of Hormuz.
Stock Impact — Indian:
| Stock | Impact | Inferred/Named | Reason |
|---|---|---|---|
| IOC | 🔴 SELL | ✅ Named (Iraq halt) | Refiner halted Iraq crude loadings — supply disruption, margin squeeze. |
| BPCL | 🔴 SELL | ⚠️ Inferred | Russian crude premium/no discount for Sep — cost pressure. May also halt Iraq loadings. |
| HPCL | 🔴 SELL | ⚠️ Inferred | Refiner — same supply disruption risk. |
| MRPL | 🔴 SELL | ✅ Named (Iraq halt) | Halting Iraq crude loadings — direct supply disruption. |
| ONGC | 🟢 BUY | ⚠️ Inferred | Upstream producer benefits from higher crude prices. |
| OIL | 🟢 BUY | ⚠️ Inferred | Same — upstream oil producer. |
| RELIANCE | 🟡 HOLD | ⚠️ Inferred | Refining margins benefit from product price spike, but crude supply disruption is a risk. Jamnagar can process diverse crude slate — advantage vs. standalone refiners. |
| TATAMOTORS | 🔴 SELL | ⚠️ Inferred | Input cost pressure from higher oil prices (transport, raw materials). |
| INDIGO | 🔴 SELL | ⚠️ Inferred | Jet fuel = 35-40% of costs. Oil at $100 crushes margins. Already reported ₹238 cr loss. |
| TATACONSUM | 🟢 BUY | ⚠️ Inferred | Defensive FMCG play. In Q1 results today, PAT up 28.4%. |
| HINDUNILVR | 🟢 BUY | ⚠️ Inferred | Defensive FMCG. Resilient to oil price shocks. |
| ADANIGREEN | 🟢 BUY | ⚠️ Inferred | High oil prices accelerate renewable energy adoption — India's import dependence is a powerful policy tailwind for renewables. |
Stock Impact — US:
| Stock | Impact | Reason |
|---|---|---|
| XOM | 🟢 BUY | Oil supermajor — highest crude price sensitivity among peers. |
| CVX | 🟢 BUY | Permian-focused, strong free cash flow at $100 oil. |
| OXY | 🟢 BUY | Most leveraged to $100+ oil among US majors. |
| EOG | 🟢 BUY | Low-cost Permian producer — breakeven ~$35/bbl, massive margin expansion. |
| HAL | 🟢 BUY | Oil services — drilling activity ramps with oil above $100. |
| SLB | 🟢 BUY | Global oil services demand sustained by elevated E&P spending. |
| COP | 🟢 BUY | ConocoPhillips — large-cap E&P with strong oil leverage. |
| DAL | 🔴 SELL | Jet fuel at $100+ crushing airline margins. |
| UAL | 🔴 SELL | Same. |
| AAL | 🔴 SELL | Highest fuel cost sensitivity. |
| CCL | 🔴 SELL | Cruise lines — fuel + itinerary disruption double hit. |
| RCL | 🔴 SELL | Same. |
| LMT | 🟢 BUY | Defence spending sustained by extended Middle East conflict. |
| PLTR | 🟢 BUY | Defence tech — AI/analytics for military operations. |
2. Generic Drug Tariff Timeline — 2-Year Grace Period Begins Aug 1
What happened: Trump's Jul 22 Truth Social post: 0% generic drug tariff from Aug 1, 2026 → Aug 1, 2028, then 100% → 200%. Structural bear for generic pharma exporters globally. Indian generic drug companies (Sun Pharma, Dr. Reddy's, Cipla, Lupin, Aurobindo) supply ~40% of US generic drug demand. The 2-year grace period provides a window for strategic adaptation.
Stock Impact:
| Stock | Impact | Inferred/Named | Reason |
|---|---|---|---|
| SUNPHARMA | 🔴 SELL | ⚠️ Inferred | Largest Indian pharma exporter to US by value. 2-year grace but structural headwind. |
| DRREDDY | 🔴 SELL | ⚠️ Inferred | ~40% revenue from US generics. |
| CIPLA | 🔴 SELL | ⚠️ Inferred | US generics exposure. Already reported PAT -39% in Q1. |
| LUPIN | 🔴 SELL | ⚠️ Inferred | High US generics revenue share. |
| AUROPHARMA | 🔴 SELL | ⚠️ Inferred | Heavy US generics exposure. |
| LLY | 🟢 BUY | ⚠️ Inferred | Branded pharma moat strengthened — generics competition faces eventual 200% tariff. |
| MRK | 🟢 BUY | ⚠️ Inferred | Same — branded pharma benefits. |
| JNJ | 🟢 BUY | ⚠️ Inferred | Diversified healthcare — minimal generic risk. |
| PFE | 🟢 BUY | ⚠️ Inferred | Bluebird pipeline protected. |
3. Section 122 Expiry — Global Importers Get Relief
What happened: The 10% Section 122 tariff expired worldwide. For most non-EU, non-USMCA economies (including China, Vietnam, Thailand, Japan, Korea, India, etc.), the replacement Section 301 forced labor tariffs kick in at 10-12.5%. For countries NOT on the 60-economy list, MFN rates resume. EU goods already moved to the 15% trade deal ceiling on Jul 1, so they're insulated. USMCA Canada/Mexico goods enter at 0%. China goods face existing Section 301 lists (7.5-100%).
Stock Impact: (Covered in Trump/US article)
📊 Summary
Global Sector Tilt:
| Sector | Signal | Key Stocks |
|---|---|---|
| Oil & Gas (US) | 🟢 BUY | XOM, CVX, OXY, EOG, HAL, SLB, COP |
| Oil & Gas (Indian upstream) | 🟢 BUY | ONGC, OIL |
| Oil Refiners (Indian) | 🔴 SELL | IOC, BPCL, HPCL, MRPL |
| Airlines (global) | 🔴 SELL | DAL, UAL, AAL, INDIGO |
| Cruises | 🔴 SELL | CCL, RCL, NCLH |
| Defence (global) | 🟢 BUY | LMT, PLTR, GD, NOC, RTX |
| Renewable Energy | 🟢 BUY | ADANIGREEN, TATAPOWER, NTPC |
| Indian Pharma | 🔴 SELL | SUNPHARMA, DRREDDY, CIPLA, LUPIN, AUROPHARMA |
| Branded Pharma (US) | 🟢 BUY | LLY, MRK, JNJ, PFE, ABBV |
| FMCG (defensive) | 🟢 BUY | ITC, HINDUNILVR, TATACONSUM |